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Increasing use of short-course antifungal therapies in patients with recurrent vulvovaginitis may enable the
emergenceof less-common,moreresistantyeaststrainsasvaginal pathogens.Wereportthe caseof a patientwith
chronically symptomatic and repeatedly treated vaginal candidiasis whose infection was attributable to Candida
lusitaniae, a previously unreported cause of candidal vaginitis.
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CASE REPORT
A 55-year-old gravida 4, para 2022 Caucasian
woman was referred for evaluation and manage-
ment of chronic recurrent vulvovaginitis. The
patient reported approximately five years of
vaginal symptoms consistingprimarily of‘burning’
and ‘itching’, with ‘outbreaks’ occurring every
1–3 months. She had been treated, in response to
symptoms and culture results, with a variety of
systemic and topical antimicrobials and antifungals
over the past years. Her most recent antifungal
therapy was 6 months prior to referral, and con-
sisted ofatwo-dosecourseoforalfluconazolewith
moderatesymptomrelief. Approximately1month
prior to referral, the patient had been treated with
a seven-day course of intravaginal clindamycin
cream after a vaginal culture was positive for
Gardnerella vaginalis; she reported only 1–2 days of
symptomatic relief after that therapy.
Thepatientwasingoodhealth,withnochronic
medical conditions. She was taking no medica-
tions. A total abdominal hysterectomy with
ovarian preservation had been performed 17 years
earlier for uterine leiomyomata. The patient
reported no menopausal vasomotor symptoms,
and was nottaking hormonereplacement therapy.
Evaluation of follicle-stimulating hormone (FSH)
and luteinizing hormone (LH) levels had recently
beenperformed inherreferring doctor’sofficeand
were not in the menopausal range.
At the time of initial evaluation, the patient
reported only minimal symptomatology. Exami-
nation revealed no redness or swelling of the
external genitalia or the vagina. No lesions or
excoriations were present. The vaginal pH was
4.5, and microscopic examination of the vaginal
secretions showed only normal-appearing epithe-
lial cells with scattered large rod-form bacteria. No
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Gynecologic case report 245treatment was instituted empirically, and vaginal
cultures obtained at that visit subsequently
returned negative both for yeast and pathogenic
bacteria. The patient was instructed to return on
symptom recurrence.
The patient returned for symptom recurrence
two monthslater. Examination was unremarkable,
vaginal pH was 4.5, and wet prep again showed
normal-appearing epithelial cells, without evi-
denceof yeast orotherpathogens.Vaginal cultures
were obtained with the fungal culture positive for
yeast, with speciation pending. Bacterial cultures
were negative. The patient was started on oral
fluconazole to begin at 200 mg every 4 days for
three doses as ‘induction’ therapy, with a plan to
begin chronic suppressive therapy if eradication of
symptoms and colonization were proven on
follow-up1. The patient returned after completing
her initial treatment, reporting that her symptoms
had improved for two days after the first dose, but
had then returned and were still present. Repeat
examination showedthepresenceofbuddingyeast
on saline prep, and a course of oral ketoconazole,
100 mg/day, was started. Five days after starting
the ketoconazole, the speciation results from the
first positive yeast culture returned as Candida
lusitaniae, with the more recent cultures again
positive for yeast (these subsequently were also
identified as C. lusitaniae). The yeast were identi-
fied in our laboratory through morphology on
cornmeal agar (Hardy Diagnostics, Santa Maria,
CA) and inoculation of an API 20 C assimilation
strip (bioMerieux, Hazelwood, MO). To elimi-
nate confusion with other yeast species, a maltose
fermentation test was performed in the laboratory
too, with absence of maltose fermentation con-
firming the presence of C. lusitaniae. The patient
was contacted and reported that she was still
symptomatic, with no relief from the keto-
conazole.Her treatment was changedto boricacid
vaginal suppositories, 600 mg nightly for 14 days.
The patient’s symptoms resolved, and a follow-up
vaginal fungal culture two weeks after completing
therapy was negative. She developed a reddened,
irritated site at the posterior forchette toward
the end of therapy, which responded to a topical
emollient cream.
DISCUSSION
While Candida albicans remains the most common
yeast species implicated in symptomatic vulvo-
vaginitis, recent reports have described a relative
decrease in its proportionalimpact compared with
a relative rise in disease attributable to non-albicans
species. One recent review calculated an increase
in non-albicans vaginal infections from 10% in the
1970s to 21% through the 1980s, with Torulopsis
glabrata and C. tropicalis demonstrating the largest
percentage increases for individual species2,3.
The change in breakdown of pathogenic yeast
species has significant implications for the treat-
ment of candidal vulvovaginitis. The widening
diversity in identified yeast strains is thought to
result at least in part from expanding use of
short-course topical imidazole antifungals, allow-
ing for the emergence of resistant organisms.
C. tropicalis and T. glabrata, for example, have been
showntoberesistanttoavarietyoftopicalprepara-
tions both in vitro and in vivo4,5, and C. tropicalis has
cell-wall characteristics that make it intrinsically
less susceptible to imidazole compounds5. Shorter
courses of less-effective regimens may also allow
for overgrowth of more resistant intravaginal yeast
species, as has been shown to be the case with the
use of low-dose antifungal prophylaxis against sys-
temic yeast infections in neutropenic or immuno-
suppressed patients6. While the shorter-course
therapies for vulvovaginitis may enhance compli-
ance for some patients, they may be insufficient or
even detrimental for those women with recurrent
symptoms who are then treated with multiple
sequential courses of both topical and systemic
antifungals, allowing the emergence of less-
sensitive non-albicans species.
The present case describes the identification of
C. lusitaniae as the pathogen responsible for the
most recent episodes of recurrent vulvovaginitis in
a chronically-treated woman, and underscores the
increased need to considersuch uncommonfungal
strains in refractory cases. C. lusitaniae was first
identified as an opportunistic human pathogen in
1979 in a patient with acute leukemia7, and has
been identified as a source of fungemia in only 42
cases reported through 20008,9. Two-thirds of
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patients, and no cases of vaginitis attributable to
C. lusitaniae in otherwise healthy women have
been reported to date. Of note is the fact that
C. lusitaniaehas beenassociated with breakthrough
fungemia in patients being treated with single-
agent antifungal regimens, though recent investi-
gators have suggested that, in their experience, the
use of fluconazole might be an effective single-
agent approach against this pathogen in immuno-
competent fungemic patients8.
Both fluconazole and ketoconazole proved
clinically and microbiologically ineffective against
the C. lusitaniae vaginitis seen in our patient. Both
agents have been shown to be effective in a high
proportionof women with recurrent vulvovaginal
candidiasis, though non-albicans species, primarily
T. glabrata, have been reported to bemore difficult
to control even with longer-duration regimens of
these systemic agents1,10. The use of boric acid to
treat vulvovaginal candidiasis was first reported in
197411, and it has been shown to be effective
against refractory non-albicans yeast species,
specifically T. glabrata12.Presented inthiscase with
a non-albicans species associated with a similarly
high degree of imidazole resistance, a treatment
regimen of intravaginal boric acid capsules as
described in Sobel’s series was employed, with
both symptomatic and bacteriologic cure against
C. lusitaniae achieved.
In reporting what we believe to be the first
reported case of recurrent vaginitis attributable to
C. lusitaniae, along with its successful treatment
with non-azole therapy, we add our concerns to
others’ over the rise of less-common, more diffi-
cult-to-treat yeast species in patients with chroni-
cally treated infections. While our patient
ultimately responded to intravaginal boric acid
therapy, this case demonstrates the value of yeast
speciation in difficult recurrent cases, and the
ongoing need to investigate newer antifungal
therapies in the face of an increasingly diverse
spectrum of pathogenic agents, even in
immunocompetent individuals.
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